Leerink Partnrs Has Optimistic Outlook of TRVI Q1 Earnings

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Stock analysts at Leerink Partnrs boosted their Q1 2025 EPS estimates for shares of Trevi Therapeutics in a research report issued to clients and investors on Tuesday, March 18th. Leerink Partnrs analyst F. Khurshid now expects that the company will post earnings of ($0.10) per share for the quarter, up from their previous forecast of ($0.13). The consensus estimate for Trevi Therapeutics' current full-year earnings is ($0.49) per share. Leerink Partnrs also issued estimates for Trevi Therapeutics' Q2 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.45) EPS and FY2026 earnings at ($0.45) EPS.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.01.

Several other equities analysts have also commented on TRVI. Needham & Company LLC cut their price target on Trevi Therapeutics from $25.00 to $24.00 and set a "buy" rating on the stock in a research note on Wednesday, March 19th. D. Boral Capital reissued a "buy" rating and set a $21.00 target price on shares of Trevi Therapeutics in a research report on Wednesday, March 19th. Raymond James raised shares of Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and upped their price target for the stock from $9.00 to $29.00 in a research report on Monday, March 10th. HC Wainwright reissued a "buy" rating and set a $12.50 price objective on shares of Trevi Therapeutics in a report on Wednesday, March 19th. Finally, B. Riley reissued a "buy" rating and issued a $20.00 price objective (up previously from $11.00) on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Seven research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $17.56.

Remove Ads

Trevi Therapeutics Stock Performance

NASDAQ TRVI traded up $0.21 on Friday, reaching $6.61. 1,053,002 shares of the stock traded hands, compared to its average volume of 994,539. Trevi Therapeutics has a 12 month low of $2.30 and a 12 month high of $7.39. The company has a market cap of $639.07 million, a price-to-earnings ratio of -15.02 and a beta of 0.90. The company has a fifty day moving average price of $4.65 and a 200-day moving average price of $3.78.

Institutional Investors Weigh In On Trevi Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Frazier Life Sciences Management L.P. grew its stake in shares of Trevi Therapeutics by 44.5% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 10,664,774 shares of the company's stock worth $43,939,000 after acquiring an additional 3,283,684 shares during the last quarter. Woodline Partners LP boosted its stake in Trevi Therapeutics by 429.9% in the 4th quarter. Woodline Partners LP now owns 3,212,597 shares of the company's stock worth $13,236,000 after purchasing an additional 2,606,370 shares in the last quarter. Squarepoint Ops LLC purchased a new stake in Trevi Therapeutics during the 4th quarter worth approximately $58,000. Two Sigma Advisers LP acquired a new position in Trevi Therapeutics during the 4th quarter valued at approximately $66,000. Finally, Two Sigma Investments LP purchased a new position in shares of Trevi Therapeutics in the fourth quarter worth $560,000. 95.76% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Trevi Therapeutics

In related news, insider Farrell Simon sold 81,313 shares of the business's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $6.75, for a total transaction of $548,862.75. Following the transaction, the insider now directly owns 76,900 shares in the company, valued at $519,075. The trade was a 51.39 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 24.37% of the company's stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.